SignalFDA/Bio

TVARDI THERAPEUTICS, INC. (TVRD) DISCUSSES PHASE 1 DATA ON TTI-109 STAT3 INHIBITOR HIGHLIGHTING PRODRUG DESIGN, TOLERABILITY AND TARGET ENGAGEMENT TRANSCRIPT - SEEKINGALPHA

Phase 1 data on TTI-109 STAT3 inhibitor provides catalyst with tolerability and target engagement.

What changed

Phase 1 data on TTI-109 STAT3 inhibitor provides catalyst with tolerability and target engagement.

Why it matters

Phase 1 data on TTI-109 STAT3 inhibitor provides catalyst with tolerability and target engagement. — impact context not separately stored; see What changed.

Sources

seekingalpha